What does the future hold for drug discovery outsourcing? Visiongain's brand new report shows you potential revenues to 2024, assessing data, trends, opportunities and prospects there. Our new study is your guide to the potential of those pharmaceutical services. It lets you assess projected sales at world market, submarket and regional level to 2024. You will see financial results, interviews, trends, opportunities, and revenue predictions. In our investigation you also see qualitative analyses, new R&D and business developments. Our 194 page report provides 152 tables, charts, and graphs. Read the full transcripts of two exclusive expert opinion interviews from leading industry specialists informing your understanding and allowing you to assess prospects for investments and sales: - Dr. Barbara Slusher, Professor of Neurology, Psychiatry, and Neuroscience, Johns Hopkins University and co-Founder and President, Academic Drug Discovery Consortium - Dr. Mark Craighead, Director of Scientific Strategy, Redx Pharma You will find prospects for key submarkets In addition to analyses of the overall world market, you will see revenue forecasting of four outsourcing submarkets at world level to 2024: • Chemical services • Biological services • Lead optimisation • Lead identification and screening With our new investigation you will gain business research and analysis with individual sales predictions and discussions. You will find analysis of competition, as well as commercial drivers and restraints. See what's likely to achieve the most success. You can win competitive advantages by understanding the trends, opportunities and challenges facing contract research organisations (CROs) in drug discovery. To see an exec summary of this report please email Sara Peerun on firstname.lastname@example.org What are the prospects in leading regions and countries? Developments worldwide will influence the market, especially rising demand in emerging countries - China, India and others. There are many opportunities for CRO service providers and pharma clients. In our study you will find individual revenue forecasts to 2024 for 12 national markets: • US • Japan • UK • Germany • France • Spain • Italy • China • India • Brazil • Russia • South Korea • RoW Emerging economies have large, highly educated workforces and competitive price regimes. Therefore countries like China and India continue to rapidly emerge as important outsourcing destinations for research and manufacturing. Greater uptake of existing technology worldwide will also stimulate the industry and market. Leading companies and potential for market growth Overall world revenue for that market area will reach $14.9bn in 2014, our work forecasts. We predict strong revenue growth from 2014 to 2024. Our work shows you what services an
PCS. A good point on BACIT. They give 1% of their net asset value to charity (50% min to ICR) and can invest another 1% to fund research involving ICR. As at Nov 2013 their NAV was £233m so they are a big contributer to ICR. ICR will have been the ones to put forward the CHK1 programme in their direction IMO
You don't bite the hand that feeds.
BACIT will want to make money as that is what they do, but for their investment in CHK1 it is more an ethical decision to get involved in line with their philosophy (ethical fund managers - how the world has changed! ). They will fully understand that nothing is guaranteed but they are willing to take the risk. And as this was their first investment deal, they must be confident. Not of outright success. If it works, everyone wins. If it doesn't, at least they tried. But confident that the main beneficiary of their charitable strategy thinks enough of it to put it forward for BACIT to get involved.
In no way is this a bad thing IMO. The risk from our (long term holder) perspective remains. Failure is a very real option. But if it does work SAR are a company with 2 potentially £1bn products under development and moving towards human trials. Plus others less advanced.
Tim will deal at some stage before those sort of values are realised, but with each little bit of progress, the price goes up.
a nice comment on toxicology in the Feb update would be very nice. But Tim and others have stated trials expected to start on 2 fronts around the end of the year. The decision everyone needs to make is what will the price be at that time?
A £10m Mcap reflects the risk. I think it is low but we are where we are. But with all of the potential, the rewards do seem to outweigh the risks.
Sold out the holding before the last agm hence didn't attend.. Seems to be settled at this price and now most projects are partnered I can't see strong price drivers until trials begin.. This is a long play this one but the rewards could be massive if just one of the molecules starts to progress through trials.. Shares like Summ and Sclp took quite a while to get going but look at them now.. Will watch and wait for a couple more months.. gl fella.
Nothing worse than somebody who comes on to a bb and starts lecturing people. There are some very good and well informed posters here, I don't include myself, that have expert knowledge on this share and must laugh when they see a blatant attempt by a ramper to build sentiment for their own ends. There are a lot of P+D crews operating on LSE and other bb's currently.
Hi All - I only have a small number of shares in SAR as I am primarily in Summit plc and like many others I am currently showing a paper loss on SAR and also I have a realised loss but I agree with PCS1954 deals are only achieved after strict due diligence. In my opinion these shares are a 'cheap as chips' and I only wish I had funds to buy more. Onwards and upwards.
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.